Atogepant

QULIPTA is indicated for the preventive treatment of migraine in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: QULIPTA is indicated for the preventive treatment of migraine in adults.
Do not take if: QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.
Reactions have included anaphylaxis and dyspnea.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hypersensitivity Reactions
Hypertension
Raynaud’s Phenomenon

Who should not take it

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea.

Storing it

Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F) [ see USP Controlled Room Temperature ].

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Atogepant; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/atogepant
APA 7th: sofidex. (2026, August 2). Atogepant. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/atogepant
AMA 11th: Atogepant. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/atogepant

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.